E. Sanches

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer.

R. Henrique, M. Teixeira, A. Peixoto, 2011, Cancer genetics.

O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial

L. Collette, P. Laurent-Puig, J. Tabernero, 2012 .

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

R. Labianca, L. Collette, A. Carrato, 2008, European journal of cancer.

Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients

M. Teixeira, S. Castedo, I. Veiga, 2004, Genetics in Medicine.